Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BCRX BioCryst Pharmaceuticals	$9.66 -0.8%	$9.92	$6.02 ▼ $11.31	$2.04B	1.11	3.02 million shs	2.56 million shs
CLDX Celldex Therapeutics	$21.17 -1.4%	$20.12	$14.40 ▼ $47.00	$1.42B	1.33	941,468 shs	746,033 shs
FOLD Amicus Therapeutics	$5.69 +0.5%	$6.30	$5.51 ▼ $12.65	$1.74B	0.54	3.10 million shs	4.15 million shs
RGLS Regulus Therapeutics	$8.16	$7.02	$0.83 ▼ $8.35	$564.95M	0.35	1.01 million shs	N/A

10 Stocks Set to Soar in Summer 2025

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BCRX BioCryst Pharmaceuticals	-0.82%	-3.01%	-10.47%	+22.90%	+56.31%
CLDX Celldex Therapeutics	-1.35%	+1.68%	+7.03%	+6.22%	-41.37%
FOLD Amicus Therapeutics	+0.53%	-0.70%	-8.81%	-32.50%	-41.34%
RGLS Regulus Therapeutics	+1.56%	-0.61%	+3.16%	+371.68%	+300.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BCRX BioCryst Pharmaceuticals	4.2011 of 5 stars	4.4	1.0	4.2	1.6	1.7	0.6
CLDX Celldex Therapeutics	2.5584 of 5 stars	4.4	3.0	0.0	2.1	0.0	0.0
FOLD Amicus Therapeutics	4.1307 of 5 stars	3.4	2.0	4.3	2.5	0.0	1.9
RGLS Regulus Therapeutics	1.4661 of 5 stars	2.1	3.0	0.0	1.9	3.3	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BCRX BioCryst Pharmaceuticals	2.89	Moderate Buy	$16.56	71.38% Upside
CLDX Celldex Therapeutics	2.89	Moderate Buy	$50.11	136.71% Upside
FOLD Amicus Therapeutics	2.70	Moderate Buy	$16.22	185.10% Upside
RGLS Regulus Therapeutics	2.29	Hold	$8.50	4.17% Upside

Current Analyst Ratings Breakdown

Latest RGLS, BCRX, FOLD, and CLDX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/25/2025	BCRX BioCryst Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$17.00
6/13/2025	CLDX Celldex Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$50.00
5/9/2025	CLDX Celldex Therapeutics	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$44.00 ➝ $38.00
5/9/2025	CLDX Celldex Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$36.00 ➝ $31.00
5/9/2025	CLDX Celldex Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$46.00 ➝ $43.00
5/7/2025	BCRX BioCryst Pharmaceuticals	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$8.00 ➝ $11.00
5/6/2025	BCRX BioCryst Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$11.00 ➝ $13.00
5/6/2025	BCRX BioCryst Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$10.00 ➝ $13.00
5/6/2025	BCRX BioCryst Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$15.00 ➝ $17.00
5/6/2025	BCRX BioCryst Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00 ➝ $30.00
5/6/2025	CLDX Celldex Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00 ➝ $80.00

(Data available from 6/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BCRX BioCryst Pharmaceuticals	$450.71M	4.48	N/A	N/A	($2.30) per share	-4.20
CLDX Celldex Therapeutics	$7.02M	200.18	N/A	N/A	$11.26 per share	1.88
FOLD Amicus Therapeutics	$528.29M	3.32	N/A	N/A	$0.65 per share	8.75
RGLS Regulus Therapeutics	N/A	N/A	N/A	N/A	$1.17 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BCRX BioCryst Pharmaceuticals	-$88.88M	-$0.26	N/A	N/A	2.20	-10.62%	N/A	-11.06%	8/4/2025 (Estimated)
CLDX Celldex Therapeutics	-$157.86M	-$2.70	N/A	N/A	N/A	-2,366.07%	-23.46%	-22.35%	8/6/2025 (Estimated)
FOLD Amicus Therapeutics	-$56.11M	-$0.09	N/A	13.23	N/A	-5.41%	4.67%	1.05%	8/14/2025 (Estimated)
RGLS Regulus Therapeutics	-$46.36M	-$0.73	N/A	N/A	N/A	N/A	-57.53%	-53.26%	8/6/2025 (Estimated)

Latest RGLS, BCRX, FOLD, and CLDX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/8/2025	Q1 2025	CLDX Celldex Therapeutics	-$0.75	-$0.81	-$0.06	-$0.81	$1.08 million	$0.70 million
5/8/2025	Q1 2025	RGLS Regulus Therapeutics	-$0.29	-$0.15	+$0.14	-$0.15	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BCRX BioCryst Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
CLDX Celldex Therapeutics	N/A	N/A	N/A	N/A	N/A
FOLD Amicus Therapeutics	N/A	N/A	N/A	N/A	N/A
RGLS Regulus Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BCRX BioCryst Pharmaceuticals	N/A	2.93	2.88
CLDX Celldex Therapeutics	N/A	21.67	21.67
FOLD Amicus Therapeutics	2.02	3.34	2.47
RGLS Regulus Therapeutics	N/A	16.31	16.31

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BCRX BioCryst Pharmaceuticals	85.88%
CLDX Celldex Therapeutics	N/A
FOLD Amicus Therapeutics	N/A
RGLS Regulus Therapeutics	92.38%

Insider Ownership

Company	Insider Ownership
BCRX BioCryst Pharmaceuticals	4.80%
CLDX Celldex Therapeutics	4.40%
FOLD Amicus Therapeutics	2.20%
RGLS Regulus Therapeutics	4.35%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BCRX BioCryst Pharmaceuticals	530	209.25 million	199.21 million	Optionable
CLDX Celldex Therapeutics	150	66.38 million	63.46 million	Optionable
FOLD Amicus Therapeutics	480	307.93 million	301.16 million	Optionable
RGLS Regulus Therapeutics	30	69.23 million	66.22 million	Optionable

RGLS, BCRX, FOLD, and CLDX Headlines

Recent News About These Companies

Novartis concludes acquisition of Regulus Therapeutics

June 26 at 10:50 AM | medicaldialogues.inM

Novartis concludes Regulus Therapeutics acquisition

June 26 at 10:50 AM | pharmaceutical-technology.comP

Press Release: Novartis completes acquisition of Regulus Therapeutics

June 25 at 1:50 PM | finanzen.atF

Novartis completes acquisition of Regulus Therapeutics

June 25 at 9:13 AM | globenewswire.com

Novartis announces expiration of HSR waiting period of Regulus Therapeutics tender offer

June 24 at 3:11 AM | pharmabiz.comP

Regulus Therapeutics Inc. (NASDAQ:RGLS) Given Consensus Recommendation of "Hold" by Brokerages

June 24 at 2:53 AM | americanbankingnews.com

Regulus Therapeutics Inc.

June 21, 2025 | barrons.com

Regulus Therapeutics (NASDAQ:RGLS) Sees Large Volume Increase - What's Next?

June 20, 2025 | marketbeat.com

Regulus Therapeutics Inc. (NASDAQ:RGLS) Receives Consensus Rating of "Hold" from Analysts

June 19, 2025 | marketbeat.com

Regulus Therapeutics (NASDAQ:RGLS) Stock Price Crosses Above Two Hundred Day Moving Average - Here's What Happened

June 18, 2025 | marketbeat.com

Regulus Therapeutics (NASDAQ:RGLS) Stock Price Passes Above Two Hundred Day Moving Average - What's Next?

June 10, 2025 | marketbeat.com

Regulus Therapeutics (NASDAQ:RGLS) Reaches New 12-Month High - Should You Buy?

June 6, 2025 | marketbeat.com

Regulus Therapeutics Inc. (NASDAQ:RGLS) Insider Buys $95,880.00 in Stock

June 5, 2025 | marketbeat.com

Regulus Therapeutics (NASDAQ:RGLS) Sees Large Volume Increase Following Insider Buying Activity

June 5, 2025 | marketbeat.com

Regulus Therapeutics Inc. (NASDAQ:RGLS) Insider Preston Klassen Acquires 12,000 Shares

June 5, 2025 | insidertrades.com

Insider Buying: Preston Klassen Acquires 12,000 Shares of Regulus Therapeutics Inc (RGLS)

June 4, 2025 | gurufocus.com

Regulus Therapeutics: An Undervalued Buy, With A $0.90 CVR And A $7 Payout

June 4, 2025 | seekingalpha.com

Regulus Therapeutics Inc. (NASDAQ:RGLS) Short Interest Update

June 2, 2025 | marketbeat.com

Millennium Management LLC Raises Position in Regulus Therapeutics Inc. (NASDAQ:RGLS)

June 1, 2025 | marketbeat.com

Northern Trust Corp Sells 40,071 Shares of Regulus Therapeutics Inc. (NASDAQ:RGLS)

June 1, 2025 | marketbeat.com

Novartis commences tender offer to acquire Regulus Therapeutics

May 29, 2025 | pharmabiz.comP

New MarketBeat Followers Over Time

Media Sentiment Over Time

RGLS, BCRX, FOLD, and CLDX Company Descriptions

BioCryst Pharmaceuticals NASDAQ:BCRX

$9.66 -0.08 (-0.82%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$9.78 +0.13 (+1.29%)

As of 06/26/2025 07:55 PM Eastern

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

Celldex Therapeutics NASDAQ:CLDX

$21.17 -0.29 (-1.35%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$21.16 -0.01 (-0.02%)

As of 06/26/2025 06:51 PM Eastern

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.

Amicus Therapeutics NASDAQ:FOLD

$5.69 +0.03 (+0.53%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$5.82 +0.13 (+2.36%)

As of 06/26/2025 07:55 PM Eastern

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.

Regulus Therapeutics NASDAQ:RGLS

$8.16 0.00 (0.00%)

As of 06/25/2025

Regulus Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time